BIM expression in EGFR-mutant non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib in Colombia.

被引：0
|
作者：
Cardona, Andres F.
Karachallou, Niki
Drozdowskyj, Ana
Gimenez Capitan, Ana
Angel Molina-Vila, Miguel
Arrieta, Oscar
Carranza, Hernan
Vargas, Carlos A.
Otero, Jorge M.
Rosell, Rafael
机构：
[1] Fdn Santa Fe Bogota, Bogota, Colombia
[2] Pangaea Biotech, Lab Translat Oncol, Barcelona, Spain
[3] Pivotal, Madrid, Spain
[4] Inst Nacl Cancerol INCAN, Mexico City, DF, Mexico
[5] Fdn Santa Fe Bogota, Clin & Traslat Oncol Grp, Bogota, Colombia
[6] Hosp Badalona Germans Trias & Pujol, USP Inst Univ Dexeus, Canc Therapeut Innovat Grp, Catalan Inst Oncol,Pangaea Biotech, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.e19098
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19098
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Updated study results of pelcitoclax (APG-1252) in combination with osimertinib in patients (pts) with EGFR-mutant non-small cell lung cancer (NSCLC).
    Zhang, Li
    Zhao, Hongyun
    Zhao, Yanqiu
    Cheng, Ying
    Cui, Jiuwei
    Ma, Yuxiang
    Yang, Chen
    Zhang, Jie
    Xu, Liang
    Yu, Juan
    Men, Lichuang
    Liang, Zhiyan
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [32] EGFR MUTATIONS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) AND CORRELATION WITH SENSITIVITY TO ERLOTINIB
    Ricciardi, S.
    Tedesco, B.
    Migliorino, M. R.
    Graziano, P.
    Leone, A.
    Di Salvia, M.
    Capodaglio, V.
    Condo, S.
    De Santis, S.
    De Marinis, F.
    EJC SUPPLEMENTS, 2008, 6 (14): : 134 - 134
  • [33] Prognostic value of EGFR genotype in EGFR-mutant non-small cell lung cancer
    Syrigos, Konstantinos
    Kotteas, Ilias
    Paraskeva, Maria
    Gkiozos, Ioannis
    Boura, Paraskevi
    Tsagouli, Sofia
    Grapsa, Dimitra
    Charpidou, Andriani
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [34] C-erbB-3 Expression in Non-small Cell Lung Cancer (NSCLC) Patients Treated by Erlotinib
    Cstoth, Ingrid
    Anthoine, Geraldine
    Berghmans, Thierry
    Mascaux, Celine
    Paesmans, Marianne
    Sculier, Jean-Paul
    Meert, Anne-Pascale
    ANTICANCER RESEARCH, 2011, 31 (01) : 281 - 285
  • [35] Outcomes and Prognostic Factors in Patients with EGFR Mutant Metastatic Non-Small Cell Lung Cancer Who Treated with Erlotinib
    Dogan, Izzet
    Khanmammadov, Nijat
    Ahmed, Melin Aydan
    Yildiz, Anil
    Saip, Pinar
    Aydiner, Adnan
    Vatansever, Sezai
    CLINICAL CANCER INVESTIGATION JOURNAL, 2022, 11 (04): : 5 - 9
  • [36] Management of EGFR-Mutant Non-Small Cell Lung Cancer: Focus on Gefitinib
    Naito, Yoichi
    Goto, Koichi
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 1027 - 1040
  • [37] Response and survival in African American (AA) patients (pts) with non-small cell lung cancer (NSCLC) treated with erlotinib (E)
    Villaflor, V. M.
    Kanteti, R.
    Watson, S. M.
    Karrison, T.
    Vokes, E. E.
    Salgia, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [38] Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors
    Yonesaka, Kimio
    Iwama, Eiji
    Hayashi, Hidetoshi
    Suzuki, Shinichiro
    Kato, Ryoji
    Watanabe, Satomi
    Takahama, Takayuki
    Tanizaki, Junko
    Tanaka, Kaoru
    Takeda, Masayuki
    Sakai, Kazuko
    Azuma, Koichi
    Chiba, Yasutaka
    Atagi, Shinji
    Nishio, Kazuto
    Okamoto, Isamu
    Nakagawa, Kazuhiko
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [39] ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung Cancer
    Desai, Aakash
    Vazquez, Tadana A.
    Arce, Keishla M.
    Corassa, Marcelo
    Mack, Philip C.
    Gray, Jhanelle E.
    Pellini, Bruna
    CANCERS, 2024, 16 (05)
  • [40] Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer
    Blaquier, Juan Bautista
    Ortiz-Cuaran, Sandra
    Ricciuti, Biagio
    Mezquita, Laura
    Cardona, Andres Felipe
    Recondo, Gonzalo
    CLINICAL CANCER RESEARCH, 2023, 29 (18) : 3579 - 3591
12345